Cellular and Molecular Neurosurgery: Pathways from Concept to Reality-Part I: Target Disorders and Concept Approaches to Gene Therapy of the Central Nervous System
- 1 April 1997
- journal article
- review article
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 40 (4) , 789-804
- https://doi.org/10.1097/00006123-199704000-00027
Abstract
RECENT ADVANCES IN cellular and molecular biology and better understanding of genetic and biochemical bases of different central nervous system (CNS) disorders have made gene therapy of the CNS a realistic goal. Concept approaches for gene therapy of CNS disorders are reviewed and include the following: 1) gene replacement with a single normal allele to correct the inherited global neurodegenerative disorders, such as enzyme deficiencies; 2) brain repair to restore the function of a particular subset of cells that were lost because of a neurodegenerative process; 3) gene therapy of brain tumors; and 4) gene therapy of stroke. Techniques of viral vector-mediated CNS transfer of a therapeutic gene, transplantation of genetically modified cells, embryonic implantation and/or implantation of genetically engineered neural progenitor cells, and production of a specific enzyme, neurotransmitter, and/or growth factor are discussed with respect to the therapeutic potential for global and localized CNS neurodegenerative disorders and stroke. Transfection of the CNS tumor cells with the drug susceptibility ("suicide") gene and/or "toxic" gene and antisense strategies and a concept of adoptive immunotherapy of brain tumors are also discussed. Other approaches, such as transfer of drug-resistant genes and monoclonal antibody gene transfer, are briefly discussed. In addition to summarizing current principles of gene therapy for several groups of CNS disorders, the issues that remain to be resolved in clinical reality, such as delivery of the genetic material and regulation of the cellular expression of the transgene, and the negatives associated with the concepts of gene therapy, such as transient gene expression, toxicity of viral proteins, drawbacks of antisense therapy, and the problem of immune response to the transfected protein, have been also identified.Keywords
This publication has 83 references indexed in Scilit:
- Gene Therapy of Parkinson Disease Model Rat by Direct Injection of Plasmid DNA–Lipofectin ComplexHuman Gene Therapy, 1995
- A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine.Proceedings of the National Academy of Sciences, 1995
- Attenuation of Stroke Size in Rats Using an Adenoviral Vector to Induce Overexpression of Interleukin-1 Receptor Antagonist in BrainJournal of Cerebral Blood Flow & Metabolism, 1995
- Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma.Proceedings of the National Academy of Sciences, 1995
- Physiological consequences of loss of plasminogen activator gene function in miceNature, 1994
- In VitroEvidence That Metabolic Cooperation Is Responsible for the Bystander Effect Observed with HSVtkRetroviral Gene TherapyHuman Gene Therapy, 1993
- Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization.Journal of Clinical Investigation, 1993
- Regression of established macroscopic liver metastases after in situ transduction of a suicide gene.Proceedings of the National Academy of Sciences, 1993
- Expression and modulation of major histocompatibility antigens on murine primary brain tumor in vitroJournal of Neurosurgery, 1991
- Human glioblastoma cell derived transforming growth factor-β2: evidence for secretion of both high and low molecular weight biologically active formsJournal of Neuroimmunology, 1991